Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
McEye Study: ALS-L1023 plus ranibizumab in neovascular (wet) age-related macular degeneration
KCT0003361Phase 2Not yet recruiting
- Sponsor
- AngioLab, Inc.
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ALS-L1023 in exudative macular degeneration, sponsored by AngioLab, Inc.. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
ALS-L1023
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on KCT0003361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003361.